ALLN-346 is under clinical development by Allena Pharmaceuticals and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ALLN-346’s likelihood of approval (LoA) and phase transition for Chronic Kidney Disease (Chronic Renal Failure) took place on 06 Nov 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 06 Nov 2021 increased ALLN-346’s LoA and PTSR for Hyperuricemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ALLN-346 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ALLN-346 overview

ALLN-346 is under development for the treatment of hyperuricemia in patients with gouty arthritis and chronic kidney disease. The drug candidate is administered through oral route. It is prepared as a recombinant enzyme using non-absorbed oral enzyme technology. It was also under development for the treatment of gout.

Allena Pharmaceuticals overview

Allena Pharmaceuticals (Allena) is a developer of oral enzyme therapeutics to treat patients with rare and severe metabolic disorders. The company develops ALLN-177 (reloxaliase), an oral recombinant oxalate degrading enzyme. Allena also develops ALLN-346, which treats hyperuricemia, gout, and chronic kidney disease. It provides ALLN-177 which is developed for the chronic management of hyperoxaluria and kidney stones. Allena designs and develops oral protein therapies to treat metabolic and orphan diseases with a particular focus on nephrologic, urologic conditions, and others. The company also holds expertise in manufacturing, formulation, non-systemic protein delivery programs, and others. Allena is headquartered in Newton, Massachusetts, US.

Quick View ALLN-346 LOA Data

Report Segments
  • Innovator
Drug Name
  • ALLN-346
Administration Pathway
  • Oral
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Metabolic Disorders
  • Musculoskeletal Disorders
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.